Showing papers by "Mariana Mitewa published in 2014"
TL;DR: Novel information is presented indicating that monensin (applied as tetraethylammonium salt) is a promising chelating agent for the treatment of Cd-induced renal and cardiac dysfunction and improved the organ weight/body weight ratios.
Abstract: Cadmium (Cd) is a well-known nephrotoxic agent. Cd-induced renal dysfunction has been considered as one of the causes leading to the development of hypertension. The correlation between Cd concentration in blood and urine and cardiovascular diseases has been discussed in many epidemiological studies. A therapy with chelating agents is utilized for the treatment of toxic metal intoxication. Herein we present novel information indicating that monensin (applied as tetraethylammonium salt) is a promising chelating agent for the treatment of Cd-induced renal and cardiac dysfunction. The study was performed using the ICR mouse model. Adult ICR male mice were divided into three groups with six animals in each group: control (received distilled water and food ad libitum for 28 days); Cd-intoxicated (treated orally with 20 mg/kg b.w. Cd(II) acetate from day 1 to day 14 of the experimental protocol), and monensin treated group (intoxicated with Cd(II) acetate as described for the Cd-intoxicated group followed by oral treatment with 16 mg/kg b.w. tetraethylammonium salt of monensic acid for 2 weeks). Cd intoxication of the animals resulted in an increase of the organ weight/body weight indexes. Cd elevated significantly creatinine and glucose level in serum. Monensin treatment improved the organ weight/body weight ratios. The therapy of the Cd-intoxicated animals with monensin ameliorated the creatinine and glucose level in serum and decreased the concentration of the toxic metal ions in the heart and kidneys by 54% and 64%, respectively.
9 citations
TL;DR: Results demonstrated that monensin could be an effective chelating agent for the treatment of Cd-induced hepatotoxicity and recovered the homeostasis of Cu and Zn.
Abstract: This study was designed to evaluate the potential application of monensin as an oral drug for the treatment of cadmium-induced hepatic dysfunction. The study was performed using ICR mouse model. Twenty-seven adult ICR male mice were divided into three groups of nine animals each: control (received distilled water and food ad libitum for 28 days); Cd-intoxicated (treated orally with 20 mg/kg b.w. Cd(II) acetate from the 1st to the 14th day of the experimental protocol); and monensin treated group (intoxicated with Cd(II) acetate as described for the Cd-intoxicated group followed by an oral treatment with 16 mg/kg b.w. tetraethylammonium salt of monensic acid for two weeks). The obtained results demonstrated that the treatment of Cd-intoxicated animals with monensin restored the liver weight/body weight index to normal values, decreased the concentration of the toxic metal ion by 50% compared to the Cd-treated controls, and recovered the homeostasis of Cu and Zn. Monensin reduced the activity of aspartate aminotransferase, alanine aminotrasnferase and alkaline phosphatase in the plasma of Cd-treated animals to the normal control levels and ameliorated the Cd-induced inflammation in the liver. Taken together, these data demonstrated that monensin could be an effective chelating agent for the treatment of Cd-induced hepatotoxicity.
5 citations
TL;DR: In this paper, an air stable Fe(II) complex of a cyclic β-triketone, 2-acetyl-1,3-indandione (2AID) was obtained in two different ways and studied by Mossbauer spectroscopy.
Abstract: An air stable Fe(II) complex of a cyclic β-triketone, 2-acetyl-1,3-indandione (2AID) was obtained in two different ways and studied by Mossbauer spectroscopy. The Mossbauer data at room temperature point to six-coordinated, high spin Fe(II) complex. The temperature-dependent measurements indicate a phase transition in going from 293 to 77 K. Further lowering the temperature, however, do not cause the expected changes for spin-crossover transition. This data provoked application of quantum chemical methods to determine the origin of the observed appearance of spectral component attributable to low spin Fe(II) complex at 77 K. Based on the results from the theoretical calculations of the Mossbauer parameters of several different geometries and spin states of the Fe complexes of 2AID it was possible to conclude that the obtained Fe(II) complex has a pseudo-octahedral geometry. The experimentally observed temperature-dependence of the Mossbauer spectra is attributed to changes of the axial Fe-O bonds, rather than to spin transition. Discussion is given on the role of the type of the axial ligands for conditioning a spin-crossover process, as suggestion for experimental modelling of novel target materials with desired magnetic properties.
1 citations